Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 5, 2024
September 4, 2024
540c1e3e-a057-4a4f-9ede-0b1290a5cf04
Related Documents
Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision: Guidance for Industry
Guidance DocumentMay 16, 2022Center for Drug Evaluation and Research
Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry: Guidance for Industry
Guidance DocumentNovember 23, 2016Center for Drug Evaluation and Research
Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products: Guidance for Industry
Guidance DocumentJuly 29, 2020Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.